Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 2 (2005), Issue 1 (January)

1. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo.
   FASEB J, 19(1): 1-11. [Abstract] [Full-text]
2. Acid-base profiling of imatinib (gleevec) and its fragments.
   J Med Chem, 48(1): 249-55. [Abstract] [Full-text]
3. Signaling function of PSGL-1 in neutrophil: tyrosine-phosphorylation-dependent and c-Abl-involved alteration in the F-actin-based cytoskeleton.
   J Cell Biochem, 94(2): 365-73. [Abstract] [Full-text]
4. Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia.
   Ann N Y Acad Sci, 1028: 423-31. [Abstract] [Full-text]
5. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib.
   Eur J Haematol, 74(2): 121-3. [Abstract] [Full-text]
6. RET signals through focal adhesion kinase in medullary thyroid cancer cells.
   Surgery, 136(6): 1212-7. [Abstract] [Full-text]
7. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
   J Clin Oncol, 23(3): 585-90. [Abstract] [Full-text]
8. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance.
   Blood, 105(3): 1135-43. [Abstract] [Full-text]
9. Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML.
   Leuk Res, 29(3): 343-5. [Abstract] [Full-text]
10. Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment.
    Leuk Res, 29(3): 287-91. [Abstract] [Full-text]
11. Imatinib inhibits the functional capacity of cultured human monocytes.
    Immunol Cell Biol, 83(1): 48-56. [Abstract] [Full-text]
12. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.
    J Am Soc Nephrol, 16(2): 363-73. [Abstract] [Full-text]
13. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.
    Proc Natl Acad Sci U S A, 102(4): 1104-9. [Abstract] [Full-text]
14. Effect of imatinib (STI571) on metastatic gastrointestinal stromal tumors: report of a case.
    Surg Today, 35(2): 157-60. [Abstract] [Full-text]
15. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
    Bone Marrow Transplant. [Abstract] [Full-text]
16. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
    J Clin Oncol, 23(4): 866-73. [Abstract] [Full-text]
17. Kit (CD117) immunoreactivity is rare in renal cell and upper urinary tract transitional cell carcinomas.
    BJU Int, 95(3): 315-8. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.